表紙
市場調査レポート

慢性蕁麻疹:パイプライン製品の分析

Chronic Urticaria Or Hives - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213077
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
慢性蕁麻疹:パイプライン製品の分析 Chronic Urticaria Or Hives - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 67 Pages
概要

慢性蕁麻疹は隆起した、様々な大きさの、赤色または白色の痒みのあるみみず腫れ(膨疹)が現れたり消えたりする症状を指します。たいていの場合、蕁麻疹は1週間以内に治まりますが、中には長期的に症状が続く人々もいます。6週間以上継続している蕁麻疹や、一旦は消失したものの頻繁に再発する蕁麻疹を慢性蕁麻疹と言います。

当レポートでは、世界各国での慢性蕁麻疹治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

慢性蕁麻疹の概要

治療薬の開発

  • パイプライン製品の概要

慢性蕁麻疹:企業で開発中の治療薬

慢性蕁麻疹:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

慢性蕁麻疹:企業で開発中の製品

慢性蕁麻疹の治療薬開発に従事している企業

  • AstraZeneca Plc
  • Biofrontera AG
  • ELORAC, Inc.
  • Faes Farma, SA
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • J Uriach Y Compania, S.A.
  • Mabtech Limited
  • Merck & Co., Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Panacea Biotec Limited

慢性蕁麻疹:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

慢性蕁麻疹:最近のパイプライン動向

慢性蕁麻疹:休止中のプロジェクト

慢性蕁麻疹:開発が中止された製品

慢性蕁麻疹:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7867IDB

Summary

Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H1 2016', provides an overview of the Chronic Urticaria Or Hives pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives
  • The report reviews pipeline therapeutics for Chronic Urticaria Or Hives by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Urticaria Or Hives therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Urticaria Or Hives therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Urticaria Or Hives Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Urticaria Or Hives - Overview
  • Chronic Urticaria Or Hives - Therapeutics under Development by Companies
  • Chronic Urticaria Or Hives - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Urticaria Or Hives - Products under Development by Companies
  • Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Biofrontera AG
    • ELORAC, Inc.
    • Faes Farma, SA
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • J Uriach Y Compania, S.A.
    • Mabtech Limited
    • Merck & Co., Inc.
    • Mycenax Biotech Inc.
    • Novartis AG
    • Panacea Biotec Limited
  • Chronic Urticaria Or Hives - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AZD-1981 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BF-Derm-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cidoxepin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desloratadine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2646264 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JDP-205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ligelizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • quilizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rupatadine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chronic Urticaria Or Hives - Recent Pipeline Updates
  • Chronic Urticaria Or Hives - Dormant Projects
  • Chronic Urticaria Or Hives - Discontinued Products
  • Chronic Urticaria Or Hives - Product Development Milestones
    • Featured News & Press Releases
      • Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico
      • Apr 27, 2007: Schering-Plough declared EU Approval of Two New Formulations of AERIUS(Desloratadine).
      • Sep 07, 2006: Schering-Plough Launched Important Multinational Studies inorder to Evaluate AERIUS (Desloratadine) Based Upon New Treatment Guidelines.
      • Aug 25, 2005: CIMA LABS' OraSolv Technology Used in CLARINEX (desloratadine) Disintegrating tablet Re-formulation.
      • Jul 15, 2005: FDA Approved Re-Formulated CLARINEX (desloratadine) Disintegrating Tablets
      • Nov 01, 2004: Clarinex syrup was approved for children.
      • May 19, 2004: Allex (Desloratadine): Withdrawal of the marketing authorization in the European Union
      • May 29, 2003: Schering-Plough declared CLARINEX Disintegrates Tablets Launched For Indoor and Outdoor Allergies and Chronic Idiopathic Urticaria. Nonsedating relief of indoor and outdoor allergies available in an orally disintegrating formulation.
      • Feb 25, 2003: Schering-Plough declared CLARINEX Granted Six Months Additional Marketing Exclusivity, Updates Status of CLARINEX Formulations.
      • Nov 22, 2002: CLARINEX(Desloratadine)was Honored With Outstanding Web Site Award By Web Marketing Association
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by AstraZeneca Plc, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Faes Farma, SA, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H1 2016
  • Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by J Uriach Y Compania, S.A., H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Mabtech Limited, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Merck & Co., Inc., H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc., H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2016
  • Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chronic Urticaria Or Hives Therapeutics - Recent Pipeline Updates, H1 2016
  • Chronic Urticaria Or Hives - Dormant Projects, H1 2016
  • Chronic Urticaria Or Hives - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Chronic Urticaria Or Hives, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top